Antibodies for stem cell-quality validation

Written by Amsbio
Company news

AMSBIO (Oxford, UK) has expanded its range of high-quality antibodies, supporting standardization and quality assurance in the fast-growing stem cell research and therapeutic field. These optimized antibodies ensure reliable, accurate results in applications including flow cytometry, immunocytochemistry, Western blot and ELISA.

New additions to the range include monoclonal antibodies against key pluripotent stem cell markers: SSEA-3 (Gb5), SSEA-4 (SialylGb5), and Lewis X (SSEA-1). Stage-Specific Embryonic Antigens (SSEA) are glycan antigens known to vary in their expression levels across the stages of embryonic development and cell differentiation. These markers are essential for evaluating undifferentiated states and early differentiation stages of human pluripotent stem cells.

These new, highly specific and reproducible antibodies are raised against glycan structures unique to human pluripotent stem cells. The resulting low cross-reactivity with non-target glycans (validated via ELISA) ensures accurate marker detection and minimizes false positives.

Stem cell specialist Phillipp Boder commented, “Not only can our strictly quality-assured antibodies help ensure your culture purity, but they also provide reliable markers for consistent research protocol assessment across different laboratories and studies.” He added, “In regenerative medicine research, our antibodies are widely proven to enhance the safety and efficacy of stem cell-based therapies by ensuring the quality and purity of cell preparations.”

For further information please click here or contact Amsbio on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected]

About AMSBIO
Now part of the Europa Biosite group of companies, AMS Biotechnology (AMSBIO) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for R&D in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices (ECMs) to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique, clinical-grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery.